Brokerages Set Allscripts (MDRX) Target Price at $16.58

Shares of Allscripts (NASDAQ:MDRX) have been given a consensus rating of “Hold” by the twenty analysts that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, five have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.58.

A number of equities research analysts recently commented on the company. Evercore ISI assumed coverage on Allscripts in a research report on Thursday, January 18th. They issued an “outperform” rating and a $17.50 price target for the company. TheStreet raised Allscripts from a “c” rating to a “b-” rating in a research report on Thursday, February 15th. BidaskClub raised Allscripts from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 price target on shares of Allscripts in a research report on Sunday, January 28th. Finally, ValuEngine lowered Allscripts from a “hold” rating to a “sell” rating in a research report on Tuesday, April 3rd.

How to Become a New Pot Stock Millionaire

NASDAQ MDRX traded up $0.10 on Thursday, reaching $12.32. The company had a trading volume of 79,778 shares, compared to its average volume of 1,986,049. The firm has a market capitalization of $2,138.99, a P/E ratio of 26.00, a PEG ratio of 1.55 and a beta of 1.23. Allscripts has a 52-week low of $10.78 and a 52-week high of $16.13. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 1.33.

Allscripts (NASDAQ:MDRX) last released its quarterly earnings results on Thursday, February 15th. The software maker reported $0.18 EPS for the quarter, meeting analysts’ consensus estimates of $0.18. The business had revenue of $547.00 million during the quarter, compared to analyst estimates of $524.05 million. Allscripts had a positive return on equity of 7.36% and a negative net margin of 10.88%. Allscripts’s quarterly revenue was up 27.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 EPS. sell-side analysts predict that Allscripts will post 0.56 EPS for the current fiscal year.

In other news, EVP Brian Farley sold 5,000 shares of the firm’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. Following the completion of the sale, the executive vice president now directly owns 240,672 shares of the company’s stock, valued at approximately $3,304,426.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Richard J. Poulton sold 15,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $13.53, for a total value of $202,950.00. Following the sale, the president now directly owns 505,920 shares of the company’s stock, valued at $6,845,097.60. The disclosure for this sale can be found here. Company insiders own 0.91% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its position in shares of Allscripts by 3.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,508,667 shares of the software maker’s stock valued at $135,308,000 after purchasing an additional 337,382 shares during the last quarter. Neuberger Berman Group LLC grew its stake in shares of Allscripts by 5.5% during the 3rd quarter. Neuberger Berman Group LLC now owns 3,676,088 shares of the software maker’s stock worth $52,311,000 after acquiring an additional 190,158 shares during the period. Dalton Greiner Hartman Maher & Co. grew its stake in shares of Allscripts by 18.4% during the 4th quarter. Dalton Greiner Hartman Maher & Co. now owns 2,990,902 shares of the software maker’s stock worth $43,518,000 after acquiring an additional 465,037 shares during the period. Fisher Asset Management LLC grew its stake in shares of Allscripts by 1.8% during the 4th quarter. Fisher Asset Management LLC now owns 2,386,237 shares of the software maker’s stock worth $34,720,000 after acquiring an additional 42,504 shares during the period. Finally, Systematic Financial Management LP grew its stake in shares of Allscripts by 14.3% during the 4th quarter. Systematic Financial Management LP now owns 2,118,015 shares of the software maker’s stock worth $30,817,000 after acquiring an additional 264,715 shares during the period.

TRADEMARK VIOLATION WARNING: This story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.chaffeybreeze.com/2018/04/17/brokerages-set-allscripts-mdrx-target-price-at-16-58.html.

About Allscripts

Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.

Analyst Recommendations for Allscripts (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply